IVDT_In Vitro Diagnostics Technology

IVD Technology, November/December 2012

Issue link: http://dc.cn.ubm-us.com/i/92152

Contents of this Issue


Page 12 of 43

TRENDS & PERSPECTIVES thing is to choose a name and then stand behind it and start using it." One Name, Multiple Markets. Th e company believes that the new name, logo, and message are right in line with the successful launch of its FilmArray system in May of 2011. "We have just initiated a clini- cal trial for our second panel [for the FilmArray instrument], which is for detecting common pathogens causing bloodstream infections," Jones said. Th e company also hopes to begin its next clinical trial in early 2013 for a gastrointestinal panel, and it is begin- ning development on panels for lower- respiratory infections and meningitis. "Th e company is focused on the suc- cess the FilmArray respiratory panel is enjoying and is planning to continue to grow our menu for clinical diagnostics," she added. While BioFire Diagnostics is chan- neling much of its energy on clinical diagnostics, it hasn't left its biodefense market behind. "BioFire is marketing FilmArray into both the clinical and biosurveillance markets," Jones said. "We think the platform off ers advan- tages to both sets of customers, although their uses are diff erent. In the biosurveillance space, customers are looking more at environmental samples that have the ability to impact civil- ians." She said that, although the clini- cal and biodefense businesses are diff er- ent, FilmArray has advantages over other technologies that will make a positive impact in both. Clinical diag- nostics, however, is more lucrative at this time. "As everyone knows, budgets are getting tighter and tighter within the government sector, which makes the sales cycle long," Jones explained. "I would say that, given the ease of use, comprehensive panel, and the time to result, hospital clinical labs have been very receptive to the technology. We are recognizing a lot of success in this market, while our growth in the biosur- veillance space has been slower." —Maureen Kingsley IVD By the Numbers $54.5 billion $440 billion 4.4% Estimated worldwide IVD sales in 2018 Estimated worth of global medtech market in 2018 Forecasted annual growth of medtech market from 2011 to 2018 Forecasted annual growth of prescription-drug market from 2011 to 2018 2.5% Source: EvaluatePharma SurModics In Vitro Diagnostics Introduces... BioFX ® TMB Extended Range HRP Microwell Substrate Increase your assay's upper limit of quantitation and maintain the detection limits and analytical sensitivity achieved with other SurModics' TMB substrates. orders@surmodics.com | 952-500-7200 | www.surmodics.com ivdtechnology.com IVD TECHNOLOGY | NOVEMBER/DECEMBER 2012 13 Visit us at MEDICA in Dusseldorf, Germany

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, November/December 2012